Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/jcpt.13303 http://scihub22266oqcxt.onion/10.1111/jcpt.13303 33098139!ä!33098139 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Clin+Pharm+Ther 2021 ; 46 (2): 440-446 Nephropedia Template TP {{tp|p=33098139|t=2021. Tocilizumab use in patients with moderate to severe COVID-19: A retrospective cohort study |pdf=|usr=}}{{33098139}} gab.com Text Tocilizumab use in patients with moderate to severe COVID-19: A retrospective cohort study JO: J Clin Pharm Ther http://www.kidney.de/pget.php?&tw=1&pmid=33098139 #FOAvip WHAT IS KNOWN AND OBJECTIVE: The coronavirus disease 2019 (COVID-19) associated cytokine activation can lead to a rapid progression into respiratory failure, shock and multiorgan failure. Interleukin-6 (IL-6) is a pro-inflammatory cytokine that likely contributes to the pathogenesis of cytokine release syndrome. It is hypothesized that modulating IL-6 levels or its effects with tocilizumab, a recombinant humanized anti-IL-6 receptor monoclonal antibody, may alter the course of disease. METHODS: We examined the association between tocilizumab use and intubation or death at a community hospital in New York City. Data were obtained regarding consecutive patients hospitalized with COVID-19. The primary end point was a composite of intubation or death in a time-to-event analysis. We compared outcomes in patients who received tocilizumab with those in patients who did not, using a multivariable Cox model with inverse probability weighting according to the propensity score. RESULTS AND DISCUSSION: In this single-centre retrospective cohort study involving 1225 hospitalized patients with SARS-CoV-2 infection, the probability to respiratory failure, which was measured as intubation or death, was less frequent in patients who received tocilizumab. WHAT IS NEW AND CONCLUSION: Tocilizumab and other IL-6 receptor monoclonal antibodies may evolve as a viable option in treating patients with moderate and severe COVID-19. Twit Text FOAVip Tocilizumab use in patients with moderate to severe COVID-19: A retrospective cohort study ????J Clin Pharm Ther http://www.kidney.de/pget.php?&tw=1&pmid=33098139 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33098139 #FOAvip English Wikipedia <ref>{{Cite pmid|33098139}}</ref> Tocilizumab use in patients with moderate to severe COVID-19: A retrospective cohort study #MMPMID33098139 Chilimuri S; Sun H; Alemam A; Kang KS; Lao P; Mantri N; Schiller L; Sharabun M; Shehi E; Tejada J; Yugay A; Nayudu SK J Clin Pharm Ther 2021[Apr]; 46 (2): 440-446 PMID33098139show ga WHAT IS KNOWN AND OBJECTIVE: The coronavirus disease 2019 (COVID-19) associated cytokine activation can lead to a rapid progression into respiratory failure, shock and multiorgan failure. Interleukin-6 (IL-6) is a pro-inflammatory cytokine that likely contributes to the pathogenesis of cytokine release syndrome. It is hypothesized that modulating IL-6 levels or its effects with tocilizumab, a recombinant humanized anti-IL-6 receptor monoclonal antibody, may alter the course of disease. METHODS: We examined the association between tocilizumab use and intubation or death at a community hospital in New York City. Data were obtained regarding consecutive patients hospitalized with COVID-19. The primary end point was a composite of intubation or death in a time-to-event analysis. We compared outcomes in patients who received tocilizumab with those in patients who did not, using a multivariable Cox model with inverse probability weighting according to the propensity score. RESULTS AND DISCUSSION: In this single-centre retrospective cohort study involving 1225 hospitalized patients with SARS-CoV-2 infection, the probability to respiratory failure, which was measured as intubation or death, was less frequent in patients who received tocilizumab. WHAT IS NEW AND CONCLUSION: Tocilizumab and other IL-6 receptor monoclonal antibodies may evolve as a viable option in treating patients with moderate and severe COVID-19. |*Antibodies, Monoclonal, Humanized/administration & dosage/adverse effects[MESH] |*COVID-19 Drug Treatment[MESH] |*COVID-19/diagnosis/immunology/mortality[MESH] |*Cytokine Release Syndrome/blood/etiology[MESH] |*Interleukin-6/antagonists & inhibitors/blood[MESH] |*Respiration, Artificial/methods/statistics & numerical data[MESH] |*SARS-CoV-2/isolation & purification[MESH] |Correlation of Data[MESH] |Female[MESH] |Hospital Mortality[MESH] |Humans[MESH] |Immunologic Factors/administration & dosage/adverse effects[MESH] |Male[MESH] |Middle Aged[MESH] |Multiple Organ Failure/etiology/prevention & control[MESH] |New York City/epidemiology[MESH] |Retrospective Studies[MESH]Tocilizumab use in patients with moderate to severe COVID-19: A retros(epmc).pdf DeepDyve Pubget Overpricing